We are in very advance stages of implementing a unique health drink / biotechnology based pharmaceuticals/ creams/ oils/ medicines (based on Aurvedic system of medicines-Indian/Amchi system of medicines- Tibetan/Chinese) in collaboration with Premier Research and Development Organizations, Govt.Of INDIA, with Creme de creme of scientists and TETRAPAK of Sweden (for all packaging of 200-250 &1000 ml packs of health drinks).

 

First phase- Health drinks- anti aging/revitalizing (Raw materials only found in Himalayan region on which we have major control, only very small scattered quantity with few others world over.)

 

Second phase- Biotechnology based pharmaceuticals and research. (medicines /oils /creams /ointments/herbal tea/nutrients for healthy cholesterol).-All technological tie ups complete (MOU signed).

First phase- Total cost- Rs. 46 Crores.(US$ 10.57 million)- in two plants- Both in HIMACHAL PRADESH. ALL TAXES AND LEVIES exempted . One plant with a capital outlay of Rs. 23 Crores(US$ 5.29 million) is in advance stages of implementation, Commercial production in Apr.-May 2010.

 
FY-2009-10
FY-2010-11
  
 
RS(m)
US$ (millions)
4.30
0.99
6.30
1.45
12.40
2.85
   
23.00
5.29
RS(Cr)
 US$ (millions)  
Financing structure for each- equity
8.60
1.98
  
GRANT (MFPI) - (Deemed equity)
12.60
2.89
  
Loans
24.80
5.70
  
       
Total
  Two plants: 46 Crores.
(US$ 10.57 million)

 

  

Second Phase- COST- Rs. 92 Crores(US$ 20.70 million). Biotechnological based pharmaceuticals –
3 rd YEAR –FY 2012

 
(Amt. in Rs.)
(Amt. in US$ Mn.)
Financing- Equity
Rs. 19.70 Crores
4.80
DEEMED EQUITY (Grant GOI)
Rs. 4.30 Crores
0.99
(Three different plants at three locations)
Loans
Rs. 68.00 Crores
14.91
     
 
92.00 Crores
20.70 mn.

IRR- (ON PAT)- 34.07% - BEP- 22.14%
Returns: Equity- Average- 20%
Guaranteed returns on Loans: 10%
Preferred financing: Long term FI/FII LOANS and part EQUITY.
Equity value appreciation (book value): 4-5 times (very conservative estimates) in two to three years.
Equity value appreciation on sector PE ratios (Average) - 10-12 times.

Our Advantage :

  • We propose to list the scrip on both Indian bourses NSE and BSE initially in 2009-10 after showing results for 2 years working at app. Book value i.e. 3-4 times- EARLIEST ROUTE.
  • Remain invested till 2 nd health drink plant and exit at 2011 at 5-6 times the base price in addition to dividends/bonus shares.
  • Remain invested till the pharmaceutical which is being launched by 2014. Appreciation by 10-12 times or may be more in addition to dividends/bonus shares.
  • Remain invested beyond 2014 when we propose to list the scrip on international bourses. We have a vision to reach turn over of 1billion $ (Approx. Rs.4800 Crores) by FY 2014 with net profits of Rs. 900-1000 Crores (220-230 million US $). Get 14-15 times value apart from the regular dividends/bonus issue shares.
  • Remain invested and harvest the fruits of enormous growth till you desire to exit at your own will and keep multiplying your wealth.

.
 
©All Rights are Reserved